Skip to Content
Print Share

Generic Prevymis Availability

Prevymis is a brand name of letermovir, approved by the FDA in the following formulation(s):

PREVYMIS (letermovir - solution;intravenous)

  • Manufacturer: MERCK SHARP DOHME
    Approval date: November 8, 2017
    Strength(s): 240MG/12ML (20MG/ML) [RLD], 480MG/24ML (20MG/ML) [RLD]

PREVYMIS (letermovir - tablet;oral)

Has a generic version of Prevymis been approved?

No. There is currently no therapeutically equivalent version of Prevymis available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Prevymis. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Patent 10,603,384

    Patent expiration dates:

    • February 28, 2033
      ✓ 
      Drug product
  • Substituted dihydroquinazolines
    Patent 7,196,086
    Issued: March 27, 2007
    Inventor(s): Wunberg; Tobias & Baumeister; Judith & Betz; Ulrich & Jeske; Mario & Lampe; Thomas & Nikolic; Susanne & Reefschläger; Jürgen & Schohe-Loop; Rudolf & Süssmeier; Frank & Zimmermann; Holger & Grosser; Rolf & Henninger; Kerstin & Hewlett; Guy & Keldenich; Jörg & Lang
    Assignee(s): Bayer HealthCare AG

    The invention relates to substituted dihydroquinazolines and to processes for their preparation and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for use as antiviral agents, in particular against cytomegalo viruses.

    Patent expiration dates:

    • May 22, 2024
      ✓ 
      Drug substance
      ✓ 
      Drug product
      ✓ 
      Sponsor has requested patent be delisted
  • Substituted dihydroquinazolines
    Patent 8,513,255
    Issued: August 20, 2013
    Assignee(s): AiCuris GmbH + Co. KG.

    The invention relates to substituted dihydroquinazolines and to processes for their preparation and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for use as antiviral agents, in particular against cytomegalo viruses.

    Patent expiration dates:

    • May 22, 2024
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Substituted dihydroquinazolines
    Patent RE46791
    Issued: April 17, 2018
    Assignee(s): AICURIS ANTI-INFECTIVE CURES GMBH

    The invention relates to substituted dihydroquinazolines and to processes for their preparation and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for use as antiviral agents, in particular against cytomegalo viruses.

    Patent expiration dates:

    • May 22, 2024
      ✓ 
      Drug substance
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • November 8, 2022 - NEW CHEMICAL ENTITY
    • November 8, 2024 -

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Drugs.com Mobile Apps

The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Available for Android and iOS devices.

Explore Apps